Table 1:
Recipient demographic and clinical characteristics by induction use/type (N=69,349)
| Variable | No induction (N=50,594) | Non-depleting (N=11,401) | Depleting (N=7,354) | P-value |
|---|---|---|---|---|
| Male, N (%) | 34,005 (67.21) | 7,491 (65.7) | 4,913 (66.81) | 0.008 |
| Age, median (IQR) | 56 (50–62) | 56 (50–62) | 56 (49–62) | 0.02 |
| Race/Ethnicity, N (%) | <0.001 | |||
| White | 36,315 (71.78) | 8,175 (71.7) | 5,488 (74.63) | |
| Black | 4,499 (8.87) | 1,024 (8.98) | 667 (9.07) | |
| Hispanic | 6,813 (13.47) | 1,545 (13.55) | 835 (11.35) | |
| Asian | 2,351 (4.65) | 451 (3.96) | 299 (4.07) | |
| Other | 627 (1.24) | 206 (1.81) | 65 (0.88) | |
| Liver disease, N (%) | <0.001 | |||
| HCV/HBV | 21,695 (42.88) | 4,383 (38.44) | 2,901 (39.45) | |
| Alcohol | 8,638 (17.07) | 2,106 (18.47) | 1,357 (18.45) | |
| Fatty liver | 8,056 (15.92) | 2,332 (20.45) | 1,345 (18.29) | |
| Auto-immune* | 5,913 (11.69) | 1,275 (11.18) | 973 (13.23) | |
| Other | 6,292 (12.44) | 1,305 (11.45) | 778 (10.58) | |
| Lab MELD, median (IQR) | 19 (13–28) | 23 (15–33) | 19 (13–28) | <0.001 |
| Dialysis at LT, N (%) | 3,888 (7.69) | 1,342 (11.8) | 550 (7.49) | <0.001 |
| HCC within Milan, N (%) | 13,139 (25.97) | 2,294 (20.12) | 1,505 (20.47) | <0.001 |
*
Includes auto-immune hepatitis, primary sclerosing cholangitis and primary biliary cirrhosis
Abbreviations: IQR – inter-quartile range; HCV – Hepatitis C virus; HBV – Hepatitis B virus; MELD – Model for End-stage Liver Disease score; LT – liver transplantation; HCC – hepatocellular carcinoma